Zacks Investment Research
03 Jul 2026, 12:46 UTC · 12w ago
Verdict
Headline takes no side. We score FHTX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Foghorn Therapeutics (FHTX) shares rose 5.8% on high volume due to investor confidence in the progress of its cancer pipeline candidates.
So whatPositive momentum in clinical pipeline progress is a primary driver for biotech valuations.
More positive than 78% of claims this week
Foghorn Therapeutics is projected to report a quarterly loss of $0.23 per share and revenues of $8.12 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 70% of claims this week
The consensus EPS estimate for Foghorn Therapeutics has remained unchanged over the last 30 days.
More negative than 64% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Shares ended the session 5.8% higher due to growing investor confidence in pipeline candidates and a Zacks Rank #2 (Buy).
More negative than 62% of ticker scores this week
Shares finished the last trading session 0.5% lower and carries a Zacks Rank of #3 (Hold).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−34.0%
Price is moving against the score
$3.50 vs $5.30 close before publication (Jul 2) · not market-adjusted
FHTX chart →